EU Seeks Views on Sanofi's Concessions to End Competition Probe

Dow Jones07-08

The European Commission is seeking feedback on a package of concessions that healthcare group Sanofi has offered to end a competition investigation into the company.

It comes after the European Union's executive arm started investigating Sanofi in June over concerns it unfairly pursued a campaign to disparage a rival flu vaccine by portraying it as inferior to its own Efluelda. Sanofi said in September 2025 the commission raided its premises over antitrust concerns.

The commission said that Sanofi offered to publish statements on its French and German websites acknowledging assessments of the vaccines carried out by the European Centre for Disease Prevention and Control and national immunisation technical advisory groups, and to avoid portraying rival CSL Seqirus's drug Fluad negatively, or claiming that Efluelda is safer or more effective. The company's commitments would be in effect until March 2030, the EU said.

"Sanofi remains confident that it has acted, and continues to act, in full compliance with all applicable laws and regulations, including competition law," a company spokesperson said, adding that Sanofi will continue to cooperate with the commission.

The regulator set an Aug. 21 deadline to receive feedback on the offer.

Write to Edith Hancock at edith.hancock@wsj.com

(END) Dow Jones Newswires

July 08, 2026 07:17 ET (11:17 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2649998271?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-08 19:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2649998271","market":"fut","top_or_hot":-1,"title":"EU Seeks Views on Sanofi's Concessions to End Competition Probe","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  The European Commission is seeking feedback on a package of concessions that healthcare group <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> has offered to end a competition investigation into the company. \n</p>\n<p>\n  It comes after the European Union's executive arm started investigating <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> in June over concerns it unfairly pursued a campaign to disparage a rival flu vaccine by portraying it as inferior to its own Efluelda. Sanofi said in September 2025 the commission raided its premises over antitrust concerns. \n</p>\n<p>\n  The commission said that Sanofi offered to publish statements on its French and German websites acknowledging assessments of the vaccines carried out by the European Centre for Disease Prevention and Control and national immunisation technical advisory groups, and to avoid portraying rival CSL Seqirus's drug Fluad negatively, or claiming that Efluelda is safer or more effective. The company's commitments would be in effect until March 2030, the EU said. \n</p>\n<p>\n  \"Sanofi remains confident that it has acted, and continues to act, in full compliance with all applicable laws and regulations, including competition law,\" a company spokesperson said, adding that Sanofi will continue to cooperate with the commission. \n</p>\n<p>\n  The regulator set an Aug. 21 deadline to receive feedback on the offer. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Edith Hancock at edith.hancock@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 08, 2026 07:17 ET (11:17 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EU Seeks Views on Sanofi's Concessions to End Competition Probe</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEU Seeks Views on Sanofi's Concessions to End Competition Probe\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-07-08 19:17</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  The European Commission is seeking feedback on a package of concessions that healthcare group <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> has offered to end a competition investigation into the company. \n</p>\n<p>\n  It comes after the European Union's executive arm started investigating <a href=\"https://laohu8.com/S/SNYNF\">Sanofi</a> in June over concerns it unfairly pursued a campaign to disparage a rival flu vaccine by portraying it as inferior to its own Efluelda. Sanofi said in September 2025 the commission raided its premises over antitrust concerns. \n</p>\n<p>\n  The commission said that Sanofi offered to publish statements on its French and German websites acknowledging assessments of the vaccines carried out by the European Centre for Disease Prevention and Control and national immunisation technical advisory groups, and to avoid portraying rival CSL Seqirus's drug Fluad negatively, or claiming that Efluelda is safer or more effective. The company's commitments would be in effect until March 2030, the EU said. \n</p>\n<p>\n  \"Sanofi remains confident that it has acted, and continues to act, in full compliance with all applicable laws and regulations, including competition law,\" a company spokesperson said, adding that Sanofi will continue to cooperate with the commission. \n</p>\n<p>\n  The regulator set an Aug. 21 deadline to receive feedback on the offer. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Edith Hancock at edith.hancock@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 08, 2026 07:17 ET (11:17 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2649998271","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2649998271","pubTimestamp":1783509420,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"The European Commission is seeking feedback on a package of concessions that healthcare group Sanofi has offered to end a competition investigation into the company.It comes after the European Union's","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4156":"煤与消费用燃料","BK4585":"ETF&股票定投概念","SNYNF":"Sanofi","SNY":"赛诺菲安万特","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","BK4007":"制药"},"translate_title":"欧盟就赛诺菲结束竞争调查的让步征求意见","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNYNF":1.5,"SNY":0.9},"content_text":"The European Commission is seeking feedback on a package of concessions that healthcare group Sanofi has offered to end a competition investigation into the company. \n\n\n  It comes after the European Union's executive arm started investigating Sanofi in June over concerns it unfairly pursued a campaign to disparage a rival flu vaccine by portraying it as inferior to its own Efluelda. Sanofi said in September 2025 the commission raided its premises over antitrust concerns. \n\n\n  The commission said that Sanofi offered to publish statements on its French and German websites acknowledging assessments of the vaccines carried out by the European Centre for Disease Prevention and Control and national immunisation technical advisory groups, and to avoid portraying rival CSL Seqirus's drug Fluad negatively, or claiming that Efluelda is safer or more effective. The company's commitments would be in effect until March 2030, the EU said. \n\n\n  \"Sanofi remains confident that it has acted, and continues to act, in full compliance with all applicable laws and regulations, including competition law,\" a company spokesperson said, adding that Sanofi will continue to cooperate with the commission. \n\n\n  The regulator set an Aug. 21 deadline to receive feedback on the offer. \n\n\n \n\n\n  Write to Edith Hancock at edith.hancock@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 08, 2026 07:17 ET (11:17 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2649998271","isCrawlerRequest":true}